Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases
Bone is the most common site of prostate cancer (PCa) progression to a therapy-resistant, lethal phenotype. We found that blockade of fibroblast growth factor receptors (FGFRs) with the receptor tyrosine kinase inhibitor dovitinib has clinical activity in a subset of men with castration-resistant PC...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , , , , , , , , , , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
American Association for the Advancement of Science
2014
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 16104caa a22021017a 4500 | ||
|---|---|---|---|
| 001 | PAPER-24062 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205551.0 | ||
| 008 | 190411s2014 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-84907289340 | |
| 024 | 7 | |2 cas |a dovitinib, 804551-71-1, 915769-50-5; fibroblast growth factor, 62031-54-3; fibroblast growth factor 2, 106096-93-9; 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one; Antineoplastic Agents; Benzimidazoles; Fibroblast Growth Factor 2; Quinolones; Receptor, Fibroblast Growth Factor, Type 1 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 100 | 1 | |a Wan, X. | |
| 245 | 1 | 0 | |a Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases |
| 260 | |b American Association for the Advancement of Science |c 2014 | ||
| 270 | 1 | 0 | |m Navone, N.M.; Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer CenterUnited States |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Carlin, B.I., Andriole, G.L., The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma (2000) Cancer, 88, pp. 2989-2994 | ||
| 504 | |a Loberg, R.D., Logothetis, C.J., Keller, E.T., Pienta, K.J., Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype (2005) J. Clin. Oncol., 23, pp. 8232-8241 | ||
| 504 | |a Turner, N., Grose, R., Fibroblast growth factor signalling: From development to cancer (2010) Nat. Rev. Cancer, 10, pp. 116-129 | ||
| 504 | |a Corn, P.G., Wang, F., McKeehen, W., Navone, N., Targeting fibroblast growth factor pathways in prostate cancer (2013) Clin. Cancer Res., 19, pp. 5856-5866 | ||
| 504 | |a Powers, C.J., McLeskey, S.W., Wellstein, A., Fibroblast growth factors, their receptors and signaling (2000) Endocr. Relat. Cancer, 7, pp. 165-197 | ||
| 504 | |a Ornitz, D.M., FGFs, heparan sulfate and FGFRs: Complex interactions essential for development (2000) Bioessays, 22, pp. 108-112 | ||
| 504 | |a Gotoh, N., Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins (2008) Cancer Sci., 99, pp. 1319-1325 | ||
| 504 | |a McKeehan, W.L., Wang, F., Kan, M., The heparan sulfate-fibroblast growth factor family: Diversity of structure and function (1998) Prog. Nucleic Acid Res. Mol. Biol., 59, pp. 135-176 | ||
| 504 | |a Acevedo, V.D., Gangula, R.D., Freeman, K.W., Li, R., Zhang, Y., Wang, F., Ayala, G.E., Spencer, D.M., Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition (2007) Cancer Cell., 12, pp. 559-571 | ||
| 504 | |a Memarzadeh, S., Xin, L., Mulholland, D.J., Mansukhani, A., Wu, H., Teitell, M.A., Witte, O.N., Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor (2007) Cancer Cell, 12, pp. 572-585 | ||
| 504 | |a Zhang, Y., Zhang, J., Lin, Y., Lan, Y., Lin, C., Xuan, J.W., Shen, M.M., Wang, F., Role of epithelial cell fibroblast growth factor receptor substrate 2α in prostate development, regeneration and tumorigenesis (2008) Development, 135, pp. 775-784 | ||
| 504 | |a Valta, M.P., Tuomela, J., Bjartell, A., Valve, E., Väänänen, H.K., Härkönen, P., FGF-8 is involved in bone metastasis of prostate cancer (2008) Int. J. Cancer, 123, pp. 22-31 | ||
| 504 | |a Li, Z.G., Mathew, P., Yang, J., Starbuck, M.W., Zurita, A.J., Liu, J., Sikes, C., Navone, N.M., Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms (2008) J. Clin. Invest., 118, pp. 2697-2710 | ||
| 504 | |a Yang, J., Fizazi, K., Peleg, S., Sikes, C.R., Raymond, A.K., Jamal, N., Hu, M., Navone, N.M., Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway (2001) Cancer Res., 61, pp. 5652-5659 | ||
| 504 | |a Roychowdhury, S., Iyer, M.K., Robinson, D.R., Lonigro, R.J., Wu, Y.M., Cao, X., Kalyana-Sundaram, S., Chinnaiyan, A.M., Personalized oncology through integrative high-throughput sequencing: A pilot study (2011) Sci. Transl. Med., 3, p. 111ra121 | ||
| 504 | |a Martin, A., David, V., Quarles, L.D., Regulation and function of the FGF23/klotho endocrine pathways (2012) Physiol. Rev., 92, pp. 131-155 | ||
| 504 | |a Wöhrle, S., Bonny, O., Beluch, N., Gaulis, S., Stamm, C., Scheibler, M., Müller, M., Graus-Porta, D., FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone (2011) J. Bone Miner. Res., 26, pp. 2486-2497 | ||
| 504 | |a Kim, K.B., Chesney, J., Robinson, D., Gardner, H., Shi, M.M., Kirkwood, J.M., Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma (2011) Clin. Cancer Res., 17, pp. 7451-7461 | ||
| 504 | |a Angevin, E., Lopez-Martin, J., Lin, C.C., Gschwend, J.E., Harzstark, A., Castellano, D., Soria, J.C., Escudier, B., Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma (2013) Clin. Cancer Res., 19, pp. 1257-1268 | ||
| 504 | |a Antonarakis, E.S., Carducci, M.A., Targeting angiogenesis for the treatment of prostate cancer (2012) Expert Opin. Ther. Targets, 16, pp. 365-376 | ||
| 504 | |a Murakami, M., Simons, M., Fibroblast growth factor regulation of neovascularization (2008) Curr. Opin. Hematol., 15, pp. 215-220 | ||
| 504 | |a O'Connor, J.P., Jackson, A., Parker, G.J., Roberts, C., Jayson, G.C., Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies (2012) Nat. Rev. Clin. Oncol., 9, pp. 167-177 | ||
| 504 | |a Murukesh, N., Dive, C., Jayson, G.C., Biomarkers of angiogenesis and their role in the development of VEGF inhibitors (2010) Br. J. Cancer, 102, pp. 8-18 | ||
| 504 | |a Jacob, A.L., Smith, C., Partanen, J., Ornitz, D.M., Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation (2006) Dev. Biol., 296, pp. 315-328 | ||
| 504 | |a Casanovas, O., Hicklin, D.J., Bergers, G., Hanahan, D., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors (2005) Cancer Cell, 8, pp. 299-309 | ||
| 504 | |a Kerbel, R.S., Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed (2005) Cancer Cell, 8, pp. 269-271 | ||
| 504 | |a Dror Michaelson, M., Regan, M.M., Oh, W.K., Kaufman, D.S., Olivier, K., Michaelson, S.Z., Spicer, B., Smith, M.R., Phase II study of sunitinib in men with advanced prostate cancer (2009) Ann. Oncol., 20, pp. 913-920 | ||
| 504 | |a Navone, N.M., Olive, M., Ozen, M., Davis, R., Troncoso, P., Tu, S.M., Johnston, D., Logothetis, C.J., Establishment of two human prostate cancer cell lines derived from a single bone metastasis (1997) Clin. Cancer Res., 3, pp. 2493-2500 | ||
| 504 | |a Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., Molina, A., Logothetis, C.J., Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone (2012) J. Clin. Oncol., 30, pp. 637-643 | ||
| 504 | |a Lonigro, R.J., Grasso, C.S., Robinson, D.R., Jing, X., Wu, Y.M., Cao, X., Quist, M.J., Chinnaiyan, A.M., Detection of somatic copy number alterations in cancer using targeted exome capture sequencing (2011) Neoplasia, 13, pp. 1019-1025 | ||
| 504 | |a Robinson, D.R., Wu, Y.M., Kalyana-Sundaram, S., Cao, X., Lonigro, R.J., Sung, Y.S., Chen, C.L., Chinnaiyan, A.M., Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing (2013) Nat. Genet., 45, pp. 180-185 | ||
| 504 | |a Han, B., Mehra, R., Dhanasekaran, S.M., Yu, J., Menon, A., Lonigro, R.J., Wang, X., Chinnaiyan, A.M., A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer (2008) Cancer Res., 68, pp. 7629-7637 | ||
| 504 | |a Yang, D., Han, L., Kundra, V., Exogenous gene expression in tumors: Noninvasive quantification with functional and anatomic imaging in a mouse model (2005) Radiology, 235, pp. 950-958 | ||
| 504 | |a Mathew, P., Thall, P.F., Bucana, C.D., Oh, W.K., Morris, M.J., Jones, D.M., Johnson, M.M., Logothetis, C.J., Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases (2007) Clin. Cancer Res., 13, pp. 5816-5824 | ||
| 504 | |a Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., Molina, A., Logothetis, C.J., Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone (2012) J. Clin. Oncol., 30, pp. 637-643 | ||
| 504 | |a Zurita, A.J., Jonasch, E., Wang, X., Khajavi, M., Yan, S., Du, D.Z., Xu, L., Heymach, J.V., A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma (2012) Ann. Oncol., 23, pp. 46-52 | ||
| 520 | 3 | |a Bone is the most common site of prostate cancer (PCa) progression to a therapy-resistant, lethal phenotype. We found that blockade of fibroblast growth factor receptors (FGFRs) with the receptor tyrosine kinase inhibitor dovitinib has clinical activity in a subset of men with castration-resistant PCa and bone metastases. Our integrated analyses suggest that FGF signaling mediates a positive feedback loop between PCa cells and bone cells and that blockade of FGFR1 in osteoblasts partially mediates the antitumor activity of dovitinib by improving bone quality and by blocking PCa cell-bone cell interaction. These findings account for clinical observations such as reductions in lesion size and intensity on bone scans, lymph node size, and tumor-specific symptoms without proportional declines in serum prostate-specific antigen concentration. Our findings suggest that targeting FGFR has therapeutic activity in advanced PCa and provide direction for the development of therapies with FGFR inhibitors. © 2014, American Association for the Advancement of Science. All rights reserved. |l eng | |
| 536 | |a Detalles de la financiación: National Institutes of Health, NIH, CA96824 | ||
| 536 | |a Detalles de la financiación: Prostate Cancer Foundation, PCF | ||
| 593 | |a Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States | ||
| 593 | |a Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, United States | ||
| 593 | |a Rolanette and Berdon Lawrence Bone Disease Program of Texas, Houston, TX 77030, United States | ||
| 593 | |a University of Athens Greece School of Medicine, Athens, 11528, Greece | ||
| 593 | |a Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States | ||
| 593 | |a Department of Biological Chemistry, University of Buenos Aires-National Research Council of Argentina (CONICET-IQUIBICEN), Ciudad Autonoma de Buenos Aires, C1428EGA, Argentina | ||
| 593 | |a Center for Cancer and Stem Cell Biology, IBT-Texas AandM Health Science Center, Houston, TX 77030, United States | ||
| 593 | |a Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States | ||
| 593 | |a Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States | ||
| 690 | 1 | 0 | |a DOVITINIB |
| 690 | 1 | 0 | |a FIBROBLAST GROWTH FACTOR |
| 690 | 1 | 0 | |a FIBROBLAST GROWTH FACTOR RECEPTOR 1 |
| 690 | 1 | 0 | |a PROSTATE SPECIFIC ANTIGEN |
| 690 | 1 | 0 | |a 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENT |
| 690 | 1 | 0 | |a BENZIMIDAZOLE DERIVATIVE |
| 690 | 1 | 0 | |a FIBROBLAST GROWTH FACTOR 2 |
| 690 | 1 | 0 | |a FIBROBLAST GROWTH FACTOR RECEPTOR 1 |
| 690 | 1 | 0 | |a QUINOLONE DERIVATIVE |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ANIMAL MODEL |
| 690 | 1 | 0 | |a ANTIANGIOGENIC ACTIVITY |
| 690 | 1 | 0 | |a ANTINEOPLASTIC ACTIVITY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a BONE METASTASIS |
| 690 | 1 | 0 | |a BONE QUALITY |
| 690 | 1 | 0 | |a BONE SCINTISCANNING |
| 690 | 1 | 0 | |a CANCER CELL |
| 690 | 1 | 0 | |a CASTRATION RESISTANT PROSTATE CANCER |
| 690 | 1 | 0 | |a CELL INTERACTION |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DRUG MEGADOSE |
| 690 | 1 | 0 | |a DRUG TARGETING |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN CELL |
| 690 | 1 | 0 | |a LOW DRUG DOSE |
| 690 | 1 | 0 | |a LYMPH NODE |
| 690 | 1 | 0 | |a LYMPH NODE SIZE |
| 690 | 1 | 0 | |a MOLECULAR INTERACTION |
| 690 | 1 | 0 | |a MOUSE |
| 690 | 1 | 0 | |a MUSCULOSKELETAL SYSTEM PARAMETERS |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a OSTEOBLAST |
| 690 | 1 | 0 | |a POSITIVE FEEDBACK |
| 690 | 1 | 0 | |a PROSTATE CANCER |
| 690 | 1 | 0 | |a PROTEIN BLOOD LEVEL |
| 690 | 1 | 0 | |a PROTEIN EXPRESSION |
| 690 | 1 | 0 | |a RECEPTOR BLOCKING |
| 690 | 1 | 0 | |a SIGNAL TRANSDUCTION |
| 690 | 1 | 0 | |a STROMA CELL |
| 690 | 1 | 0 | |a TUMOR MICROENVIRONMENT |
| 690 | 1 | 0 | |a TUMOR VOLUME |
| 690 | 1 | 0 | |a ANIMAL |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a BONE |
| 690 | 1 | 0 | |a BONE NEOPLASMS |
| 690 | 1 | 0 | |a DISEASE MODEL |
| 690 | 1 | 0 | |a DRUG EFFECTS |
| 690 | 1 | 0 | |a DRUG SCREENING |
| 690 | 1 | 0 | |a GENE EXPRESSION REGULATION |
| 690 | 1 | 0 | |a GENETICS |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a METABOLISM |
| 690 | 1 | 0 | |a NEOVASCULARIZATION, PATHOLOGIC |
| 690 | 1 | 0 | |a PATHOLOGY |
| 690 | 1 | 0 | |a PROSTATIC NEOPLASMS |
| 690 | 1 | 0 | |a SECONDARY |
| 690 | 1 | 0 | |a STROMA CELL |
| 690 | 1 | 0 | |a TUMOR CELL LINE |
| 690 | 1 | 0 | |a VASCULARIZATION |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENTS |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a BENZIMIDAZOLES |
| 690 | 1 | 0 | |a BONE AND BONES |
| 690 | 1 | 0 | |a BONE NEOPLASMS |
| 690 | 1 | 0 | |a CELL LINE, TUMOR |
| 690 | 1 | 0 | |a DISEASE MODELS, ANIMAL |
| 690 | 1 | 0 | |a FIBROBLAST GROWTH FACTOR 2 |
| 690 | 1 | 0 | |a GENE EXPRESSION REGULATION, NEOPLASTIC |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MICE |
| 690 | 1 | 0 | |a NEOVASCULARIZATION, PATHOLOGIC |
| 690 | 1 | 0 | |a OSTEOBLASTS |
| 690 | 1 | 0 | |a PROSTATIC NEOPLASMS |
| 690 | 1 | 0 | |a PROSTATIC NEOPLASMS, CASTRATION-RESISTANT |
| 690 | 1 | 0 | |a QUINOLONES |
| 690 | 1 | 0 | |a RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1 |
| 690 | 1 | 0 | |a SIGNAL TRANSDUCTION |
| 690 | 1 | 0 | |a STROMAL CELLS |
| 690 | 1 | 0 | |a TUMOR MICROENVIRONMENT |
| 690 | 1 | 0 | |a XENOGRAFT MODEL ANTITUMOR ASSAYS |
| 700 | 1 | |a Corn, P.G. | |
| 700 | 1 | |a Yang, J. | |
| 700 | 1 | |a Palanisamy, N. | |
| 700 | 1 | |a Starbuck, M.W. | |
| 700 | 1 | |a Efstathiou, E. | |
| 700 | 1 | |a Li-Ning Tapia, E.M. | |
| 700 | 1 | |a Zurita, A.J. | |
| 700 | 1 | |a Aparicio, A. | |
| 700 | 1 | |a Ravoori, M.K. | |
| 700 | 1 | |a Vazquez, E.S. | |
| 700 | 1 | |a Robinson, D.R. | |
| 700 | 1 | |a Wu, Y.-M. | |
| 700 | 1 | |a Cao, X. | |
| 700 | 1 | |a Iyer, M.K. | |
| 700 | 1 | |a McKeehan, W. | |
| 700 | 1 | |a Kundra, V. | |
| 700 | 1 | |a Wang, F. | |
| 700 | 1 | |a Troncoso, P. | |
| 700 | 1 | |a Chinnaiyan, A.M. | |
| 700 | 1 | |a Logothetis, C.J. | |
| 700 | 1 | |a Navone, N.M. | |
| 773 | 0 | |d American Association for the Advancement of Science, 2014 |g v. 6 |k n. 252 |p Sci. Transl. Med. |x 19466234 |t Science Translational Medicine | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907289340&doi=10.1126%2fscitranslmed.3009332&partnerID=40&md5=4fb8692163daa58830555a3e8b9422e5 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1126/scitranslmed.3009332 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_19466234_v6_n252_p_Wan |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_19466234_v6_n252_p_Wan |y Registro en la Biblioteca Digital |
| 961 | |a paper_19466234_v6_n252_p_Wan |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 85015 | ||